Dr Reddys launches Reddy-Lenalidomide in Canada

Approval for this indication is based on red blood cell transfusion independence response rates. Overall survival benefit has not been demonstrated. Reddy-Lenalidomide in combination with dexamethasone is indicated for the treatment of multiple myeloma patients who are not eligible for stem cell transplant.

"Our launch of Reddy-Lenalidomide represents our firm commitment to providing access to affordable medicines for Canada's Multiple Myeloma and Myelodysplastic Syndrome (MDS) patient population," says Vinod Ramachandran, Ph.D., Vice President and General Manager, Dr. Reddy's Laboratories Canada. "Along with this important launch, we are pleased to introduce our Reddy2Assist Platform, which provides convenient one-stop access to assist prescribers and pharmacists with qualification requirements for patients, as well as patient on boarding and registration via web portal, telephone or fax."

Reddy-Lenalidomide capsules are available in 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg strengths, each in blister packs.

Read also: Dr Reddys launches generic Librax in US